CN114224778A - Schizophyllum commune polysaccharide composition and preparation method and application thereof - Google Patents
Schizophyllum commune polysaccharide composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN114224778A CN114224778A CN202111615861.7A CN202111615861A CN114224778A CN 114224778 A CN114224778 A CN 114224778A CN 202111615861 A CN202111615861 A CN 202111615861A CN 114224778 A CN114224778 A CN 114224778A
- Authority
- CN
- China
- Prior art keywords
- schizophyllan
- composition
- ergothioneine
- preparation
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention provides a schizophyllan composition, a preparation method and application thereof. The composition of schizophyllan includes schizophyllan and ergothioneine. The schizophyllan composition can enhance the oxidation resistance of skin tissues, reduce the free radical content of skin tissue cells and play a role in delaying skin photoaging.
Description
Technical Field
The invention belongs to the field of cosmetics, and particularly relates to a schizophyllan composition, and a preparation method and application thereof.
Background
The human body constantly generates free radicals in the human body due to continuous contact with the outside, including respiration (oxidation reaction), external pollution, radiation irradiation, and the like. Research has shown that free radicals are one of the important factors leading to human aging. Various free radicals exist in the human body, such as superoxide anion radical, hydroxyl radical, DPPH radical, etc., which can break down cells and tissues, affecting metabolic function. In addition to normal metabolism, the concentration of free radicals in the body is affected by factors such as solar radiation, pollution, exercise level, mental state, and the like.
Antioxidant is any substance that is present at low concentrations to effectively inhibit the oxidation of free radicals, either by acting directly on the free radicals or by indirectly consuming substances that readily form free radicals, preventing further reactions from occurring. The antioxidant can eliminate excessive free radicals, is helpful for delaying body degeneration and delaying skin aging, and has prevention effect on diseases caused by many free radicals and aging related diseases.
The human body can generate free radicals and simultaneously generate antioxidant substances for resisting the free radicals, but with the aging of the human body, the quantity of superoxide dismutase, catalase and the like in a natural protection system can be reduced, the unabated free radicals can cause adverse effects on the skin, including crosslinking and aging of collagen, obvious wrinkles appear in the hypoelasticity of the skin, and even the structure and the function of cell membranes and extracellular mesenchymal lipids can be changed.
CN112353800a9 discloses the use of hyaluronic acid or a salt thereof and/or trehalose for stabilizing ergothioneine, an additive for stabilizing ergothioneine, the additive comprising hyaluronic acid or a salt thereof and/or trehalose, and a composition comprising ergothioneine, hyaluronic acid or a salt thereof, and trehalose. Compared with other auxiliary materials, the hyaluronic acid or the salt thereof and the trehalose provided by the invention can obviously relieve the damage of high temperature to ergothioneine and improve the yield of ergothioneine powder products, but the capacity of the composition for scavenging free radicals and resisting oxidation needs to be improved.
CN110327242A discloses a method for inhibiting ergothioneine photodegradation and application thereof, comprising the following steps: adding hyaluronate to a solution containing ergothioneine; the content of the ergothioneine is 0.0005-0.01 wt%; the content of the hyaluronate is more than 0.1 wt%. In the method, the purpose of inhibiting the photodecomposition of ergothioneine is achieved by adding the combination of the hyaluronate with different molecular weight distributions, but the hyaluronate with the molecular weight distribution has a common antioxidant effect, and the effect of further improving the comprehensive antioxidant effect is difficult to achieve only by depending on the ergothioneine.
CN112535644A discloses ergothioneine lipid complex gel and a preparation method thereof, belonging to the technical field of high polymer materials. The compound gel of the invention is prepared from the following raw materials in parts by weight: 1 part of ergothioneine, 8-20 parts of phospholipid, 0.2-1.5 parts of polyol ester, 10-20 parts of carbomer, 60-150 parts of glycerol, 10-50 parts of propylene glycol, 5-20 parts of N-trimethyl chitosan and 0.1-0.2 part of carbazone. The invention forms stable ergothioneine lipid complex by coating the active substance ergothioneine with polyol ester and phospholipid, and the obtained final product improves the stability of the ergothioneine, but the capacity of the composition for scavenging free radicals and resisting oxidation also needs to be improved.
CN107674129A discloses a phosphorylated schizophyllan derivative, a preparation method and an application thereof, wherein the phosphorylated schizophyllan derivative is prepared from the following raw materials in percentage by mass: 1-10% of schizophyllan, 1.5-20% of phosphorylation reagent and the balance of solvent; the preparation method of phosphorylated schizophyllan derivatives comprises the following steps: (1) adding schizophyllan and a phosphorylation reagent into a solvent, and mixing and stirring for reaction; (2) separating and purifying the reaction liquid to obtain the phosphorylated derivatives of schizophyllan. The method further improves the antioxidant activity of schizophyllan through phosphorylation treatment, the preparation process is complex, translation is usually required for more than 5 hours, and post treatment is required to repeatedly redissolve and purify precipitates; the prepared phosphorylated schizophyllan derivative has good moisture retention, but the antioxidant effect needs to be improved.
Therefore, there is a need to develop a schizophyllan composition with more comprehensive antioxidant effect, which can be used as an antioxidant active ingredient in skin care products.
Disclosure of Invention
In view of the deficiencies of the prior art, it is an object of the present invention to provide compositions of schizophyllan and methods of making and using the same. The schizophyllan composition can enhance the antioxidant capacity of skin tissues, reduce the free radical content of skin tissue cells and play a role in delaying skin photoaging.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a composition of schizophyllan, comprising schizophyllan and ergothioneine.
In the invention, the schizophyllan and the ergothioneine are mutually matched, have a synergistic effect, can further improve the scavenging effect of the composition on DPPH free radicals, hydroxyl free radicals and superoxide anion free radicals, can enhance the antioxidant capacity of skin tissues, reduce the free radical content of the skin tissues and play a role in delaying skin photoaging.
Wherein the Schizophyllum commune polysaccharide is a natural beta-D-glucan produced from Schizophyllum commune, is composed of a (1-3) -linked beta-D-glucopyranose residue main chain and a side chain of a (1-6) -linked glucopyranose residue, and has antioxidant and radioprotective effects. The schizophyllan can inhibit the generation of free radicals by inhibiting oxidase system and complexing oxidized transition metal ions; can exert the anti-radiation effect by eliminating free radicals, regulating gene expression, protein synthesis and other ways, prolong the apoptosis time of radiation-damaged cells and inhibit lipid peroxidation. However, the solubility of schizophyllan in water is low and can be generally improved by chemically or physically modifying it; the invention surprisingly discovers that the ergothioneine and the ergothioneine have synergistic effect to further improve the antioxidant capacity of the composition, and the ergothioneine can remarkably improve the stability of the schizophyllan, improve the viscosity of the schizophyllan and further improve the solubility of the schizophyllan.
Wherein ergothioneine is a natural small molecule amino acid, chemically 2-mercapto-L-histidine trimethyl inner salt or mercaptohistidine trimethyl inner salt, which is a powerful hypochloride scavenger (HOCl) that protects erythrocytes from neutrophils from normal functional or pathological inflammatory sites; also can inhibit the oxidation of amino acid in peroxynitroso anion medium; minimize the formation of reactive oxygen species, protect against damage caused by ultraviolet and gamma radiation, and protect cells from radiation damage. Ergothioneine is a small-molecule water-soluble amino acid, and has the defects of easy decomposition under visible light and poor stability. The present inventors have surprisingly found that schizophyllan is complexed with ergothioneine. The schizophyllan can obviously improve the stability of ergothioneine and inhibit the photodegradation of the ergothioneine.
Preferably, the mass ratio of the schizophyllan to the ergothioneine is (0.1-10): (0.5-2);
wherein "0.1 to 10" may be, for example, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.;
here, "0.5 to 2" may be, for example, 0.5, 0.6, 0.8, 1, 1.2, 1.4, 1.6, 2 or the like.
Preferably, the schizophyllan comprises any one of, or a combination of at least two of, oligomeric schizophyllan, small molecule schizophyllan, intermediate molecule schizophyllan, or large molecule schizophyllan.
Preferably, the oligomeric schizophyllan has a molecular weight of less than 10kD, and may be, for example, 9.9kD, 9kD, 8kD, 7kD, 6kD, 5kD, 4kD, 3kD, 2kD, 1kD, 0.5kD, 0.1kD, or the like.
Preferably, the molecular weight of the small molecule schizophyllan is 10-100kD, such as 10kD, 20kD, 30kD, 40kD, 50kD, 60kD, 70kD, 80kD, 90kD, 99kD, 99.9kD, etc., excluding 100 kD.
Preferably, the molecular weight of the intermediate molecular schizophyllan is 100-1000kD, such as 100kD, 200kD, 300kD, 400kD, 500kD, 600kD, 700kD, 800kD, 900kD, 999kD, 999.9kD, etc., and does not include 1000 kD.
Preferably, the molecular weight of the macromolecular schizophyllan is 1000-2000kD, such as 1000kD, 1100kD, 1200kD, 1300kD, 1400kD, 1500kD, 1600kD, 1700kD, 1800kD, 1900kD, 2000kD, etc.
Preferably, the schizophyllan is an oligomeric schizophyllan, the mass ratio of oligomeric schizophyllan to ergothioneine being (2-4: 1, which may be, for example, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, etc.
Preferably, the schizophyllan is a small molecule schizophyllan, the mass ratio of the small molecule schizophyllan to ergothioneine is (5-10):1, and may be, for example, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, etc.
Preferably, the schizophyllan is a medium molecular schizophyllan, the mass ratio of the medium molecular schizophyllan to ergothioneine is (1-2):1, and may be, for example, 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1, 2:1, etc.
Preferably, the schizophyllan is a macromolecular schizophyllan, the mass ratio of the macromolecular schizophyllan to ergothioneine being (0.5-2):1, and may be, for example, 0.5:1, 0.6:1, 0.8:1, 1:1, 1.2:1, 1.4:1, 1.6:1, 1.8:1, 2:1, etc.
Preferably, the composition of schizophyllan also comprises a solvent.
Preferably, the solvent comprises water.
Preferably, the composition of the schizophyllan comprises the following components in percentage by mass: 0.01-10% (e.g., 0.01%, 0.05%, 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, etc.) and 0.05-2% (e.g., 0.05%, 0.1%, 0.5%, 1%, 1.5%, 2%, etc.) of ergothioneine, with the balance being water.
In a second aspect, the present invention provides a process for preparing a composition of schizophyllan as described in the first aspect, comprising the steps of: mixing schizophyllan and ergothioneine to obtain the composition of schizophyllan.
Preferably, the mixing is carried out in a solvent.
Preferably, the mixing temperature is 50-90 deg.C, such as 50 deg.C, 60 deg.C, 70 deg.C, 80 deg.C, 82 deg.C, 84 deg.C, 86 deg.C, 88 deg.C, 90 deg.C, etc., and the mixing time is 10-50min, such as 10min, 20min, 25min, 30min, 35min, 40min, 45min, 50min, etc.
In a third aspect, the present invention provides the use of a composition of schizophyllan as described in the first aspect for the preparation of an antioxidant product.
Preferably, the antioxidant product is an antioxidant cosmetic.
Preferably, the cosmetic comprises any one of cream, lotion, emulsion, essence oil or mask.
In a fourth aspect, the present invention provides a cosmetic product according to the first aspect, comprising the composition of schizophyllan according to the first aspect.
Preferably, the amount of the composition of schizophyllan added is 0.01 to 50% of the total mass of the cosmetic, for example, 0.01%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, etc., preferably 0.05 to 20%.
Compared with the prior art, the invention has the following beneficial effects:
(1) the schizophyllan and the ergothioneine are matched with each other to have a synergistic effect, so that the removal effect of the composition on DPPH free radicals, hydroxyl free radicals and superoxide anion free radicals can be further improved, the oxidation resistance of skin tissues can be enhanced, the free radical content of the skin tissues can be reduced, and the effect of delaying skin photoaging can be achieved;
(2) the composition of the schizophyllan has good capacities of resisting oxidation and removing DPPH free radicals, the removal rate of superoxide anion free radicals is more than 50%, the removal rate of hydroxyl free radicals is more than 50%, and the inhibition rate of DPPH free radicals is more than 80%;
(3) the schizophyllan composition has good anti-photoaging effect, can limit and improve the Hyp content in skin tissues and the SOD activity in blood of mice of a photoaging model, the SOD activity is maintained to be more than 105U/mL, and the HYP content is more than 8 mug/mg.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
The following examples and comparative examples, where no specific techniques or conditions are indicated, can be performed according to the techniques or conditions described in the literature in the art or according to the product specifications. The reagents or apparatus used are conventional products commercially available from a formal channel or may be prepared by the prior art, without reference to the manufacturer.
Example 1
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.3 percent of oligomeric schizophyllan with the average molecular weight of 8kD, 0.1 percent of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing the schizophyllan and ergothioneine in water at 50 deg.C for 15min to obtain the composition.
Example 2
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.4% of oligomeric schizophyllan with the average molecular weight of 5kD, 0.2% of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing the above formula amounts of schizophyllan and ergothioneine in water at 60 deg.C for 10min to obtain the composition of schizophyllan.
Example 3
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.4% of oligomeric schizophyllan with the average molecular weight of 2kD, 0.1% of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing the above formula amounts of schizophyllan and ergothioneine in water at 55 deg.C for 20min to obtain the composition of schizophyllan.
Example 4
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.5 percent of micromolecule schizophyllan with the average molecular weight of 80kD, 0.05 percent of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing the above formula amount of small molecule schizophyllan and ergothioneine in water at 70 deg.C for 10min to obtain the composition of schizophyllan.
Example 5
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.6 percent of micromolecule schizophyllan with average molecular weight of 60kD, 0.1 percent of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing the above formula amount of small molecule schizophyllan and ergothioneine in water at 65 deg.C for 12min to obtain the composition of schizophyllan.
Example 6
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.4 percent of micromolecule schizophyllan with average molecular weight of 30kD, 0.08 percent of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing the above formula amount of small molecule schizophyllan and ergothioneine in water at 70 deg.C for 10min to obtain the composition of schizophyllan.
Example 7
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.6 percent of middle molecular schizophyllan with the average molecular weight of 800kD, 0.6 percent of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing molecular schizophyllan and ergothioneine in the formula amount in water at 72 deg.C for 15min to obtain the composition of schizophyllan.
Example 8
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.8 percent of middle molecular schizophyllan with the average molecular weight of 400kD, 0.4 percent of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing molecular schizophyllan and ergothioneine in the formula amount in water at 75 deg.C for 20min to obtain the composition of schizophyllan.
Example 9
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: 0.5 percent of macromolecular schizophyllan with the average molecular weight of 1200kD, 1 percent of ergothioneine and the balance of water;
the preparation method of the schizophyllan composition comprises the following steps: mixing the macromolecular schizophyllan and ergothioneine with the formula amount in water at 80 ℃ for 20min to obtain the schizophyllan composition.
Example 10
The embodiment provides a composition of schizophyllan, which comprises the following components in percentage by mass: macromolecular schizophyllan with average molecular weight of 1000kD 1.0%, ergothioneine 0.5%, and water in balance;
the preparation method of the schizophyllan composition comprises the following steps: mixing the macromolecular schizophyllan and ergothioneine with the formula amount in water at 82 deg.C for 25min to obtain the composition of schizophyllan.
Comparative example 1
This comparative example provides an aqueous solution of ergothioneine having a 0.4% mass percent ergothioneine content.
Comparative example 2
This comparative example provides an aqueous solution of oligomeric Schizophyllan having a mass percent of 0.4% and an average molecular weight of 8 kD.
Comparative example 3
This comparative example provides an aqueous solution of a small molecule schizophyllan having a mass percent of 0.55% and an average molecular weight of 80 kD.
Comparative example 4
This comparative example provides an aqueous solution of a molecular schizophyllan having a mass percent of 1.2% and an average molecular weight of 800 kD.
Comparative example 5
The comparative example provides an aqueous solution of a macromolecular schizophyllan having a mass percent of macromolecular schizophyllan of 1.5% and an average molecular weight of 1200 kD.
Test example 1
Irritation testing machine evaluation method (skin seal patch test)
Test samples: the schizophyllan compositions provided in examples 1-10 and the aqueous solutions provided in comparative examples 1-5;
the test method comprises the following steps: 1. the subject was enrolled with selection criteria to participate in 30 panelists. 2. The test samples were loaded into the plaque tester chambers, and one group was selected as a blank control, and the plaque tester was taped to the forearm flexor of the subject for 24 h. 3. Respectively observing skin reactions 48 hours after the test object spot tester is removed, wherein the skin reaction grading standard of the skin closed type spot test is shown in table 1, and the specific test result is shown in table 2:
TABLE 1
TABLE 2
As can be seen from the test results in Table 2, in the skin-sealing patch test, after the schizophyllan composition provided in examples 1-10 of the present invention is applied for 48 hours, the subjects did not show any reaction and no adverse reaction, such as erythema, burning sensation or itching. The enclosed patch test shows that the schizophyllan composition of the invention has no irritation to the skin.
Test example 2
Free radical scavenging test
Test samples: the schizophyllan compositions provided in examples 1-10 and the aqueous solutions provided in comparative examples 1-5;
the test method comprises the following steps:
1. evaluation of superoxide anion radical scavenging ability
4.5mL of Tris-HCl buffer (0.05 mol/LpH ═ 8.2) was preheated in a water bath at 25 ℃ for 20 min. Then adding 1mL of sample and 0.4mL of 25mmol/L pyrogallol solution, mixing uniformly, reacting in a water bath at 25 ℃ for 5min, and adding 1.0mL of 8mol/L HCl to terminate the reaction. Absorbance values were measured at 299nm with Tris-HCl buffer as a reference. Blank control 1mL of sample in solvent was used instead of sample.
Superoxide anion radical scavenging rate (%) ([ 1- (A)2/A1)]×100％
In the formula A1Absorbance values for the blank; a. the2Is the absorbance value of the sample.
2. Evaluation of hydroxyl radical scavenging ability
Sequentially adding 2mmol/L FeSO into a 25mL colorimetric tube43 mL，1mmol/L H2O23mL, shaking up, then adding 3mL of salicylic acid with the concentration of 6mmol/L, shaking up, heating in a water bath at 37 ℃ for 15min, taking out, and measuring the absorbance; adding the solutions to be tested with certain concentrations, shaking, heating in water bath for 15min, and taking out to test their absorbance. The following formula is the clearance rate of hydroxyl radical (. OH) by the liquid to be tested:
hydroxyl radical clearance (%) ═ a1－A2－(A1－A3)]/A1×100％
In the formula A1The absorbance value of the reaction system before adding the medicine is obtained; a. the2Removing OH from the sample to obtain the absorbance value of the system; a. the3Removing OH for blank control to obtain absorbance value of the system;
3. evaluation of scavenging ability for DPPH free radical
Test A20 mmol/L DPPH solution was prepared according to the method specified in Larrauri JA; test sample solution: the schizophyllan compositions provided in examples 1-10 and the compositions provided in comparative examples 1-5 were diluted with ultrapure water to give solutions having a mass concentration of 0.1%. Putting 2.0mL of test sample solution and 2.0mL of 20mmol/L DPPH solution in a test tube, mixing uniformly, reacting for 30min, measuring absorbance value at 517nm, taking absolute ethyl alcohol as blank control, and calculating DPPH inhibition ratio according to the absorbance value.
DPPH radical inhibition (%) - [1- (A)1-A2)/A3]×100％；
Wherein A is1Absorbance of 2.0mL of DPPH solution and 2.0mL of test sample solution, A2Absorbance of 2.0mL of the test sample solution and 2.0mL of anhydrous ethanol, A3The absorbance of 2.0mL of DPPH solution and 2.0mL of absolute ethyl alcohol is obtained, and the average value is obtained by parallel testing for three times;
the specific test results are shown in table 3:
TABLE 3
As shown in the test data in Table 3, the schizophyllan composition has good capacities of resisting oxidation and removing DPPH free radicals, the removal rate of superoxide anion free radicals is more than 50%, the removal rate of hydroxyl free radicals is more than 50%, and the inhibition rate of DPPH free radicals is more than 80%. Fully shows that the schizophyllan and the ergothioneine are mutually matched, have a synergistic effect, can further improve the scavenging effect of the composition on DPPH free radicals, hydroxyl free radicals and superoxide anion free radicals, can enhance the antioxidant capacity of skin tissues, reduce the free radical content of the skin tissues, and play a role in delaying skin photoaging.
Test example 3
Radiation resistance test
Test samples: the schizophyllan compositions provided in examples 1-10 and the aqueous solutions provided in comparative examples 1-5;
the test method comprises the following steps: establishing a mouse model: female ICR mice of 6-8 weeks of age were acclimatized for one week and then randomly divided into 17 groups (including model group, normal group and sample 1-15 groups, wherein the sample 1-15 groups correspond to the schizophyllan composition provided in examples 1-10 and the composition provided in comparative examples 1-5, and the model group and the normal group were given the same volume of distilled water) based on body weight.
Except for the normal group, the back hairs of the other groups are shaved off, and the UVA and the UVB are simultaneously irradiated at a distance of 10cm from a light source by a daily simulated sunlight irradiator (UVA, 80-100W, the wavelength of 320-400nm, the length of 120 cm; UVB, 80-100W, the wavelength of 290-320nm, the length of 120 cm) for 8 weeks and 3 hours every day to form a mouse photoaging model; after 8 weeks, the animals were sacrificed, the whole skin of the depilated area of the back was removed, and the SOD activity and HYP content were measured;
the specific test results are shown in table 4:
TABLE 4
The test results in Table 4 show that the schizophyllan composition can improve the Hyp content in the skin tissues and the SOD activity in the blood of mice in a photoaging model, the SOD activity is maintained to be more than 105U/mL, the HYP content is more than 8 mu g/mg, and the schizophyllan composition has a protective effect on the skin of the mice. Fully shows that the schizophyllan and the ergothioneine are mutually matched, have a synergistic effect, and can further effectively prevent, relieve and treat various skin problems such as skin sunburn and the like caused by photoaging.
The applicant states that the present invention is illustrated by the above examples of the composition of the split polysaccharides of the present invention and the preparation method and application thereof, but the present invention is not limited to the above examples, i.e. it does not mean that the present invention must be implemented by the above examples. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
Claims (10)
1. A schizophyllan composition, wherein the schizophyllan composition comprises schizophyllan and ergothioneine.
2. The composition of schizophyllan of claim 1, wherein the mass ratio of schizophyllan to ergothioneine is (0.1-10): (0.5-2).
3. The composition of claim 1 or 2, wherein the schizophyllan comprises any one of or a combination of at least two of oligomeric schizophyllan, small molecule schizophyllan, intermediate molecule schizophyllan, or large molecule schizophyllan;
preferably, the oligomeric schizophyllan has a molecular weight of less than 10 kD;
preferably, the small molecule schizophyllan has a molecular weight of 10-100 kD;
preferably, the molecular weight of the middle molecular schizophyllan is 100-1000 kD;
preferably, the molecular weight of the macromolecular schizophyllan is 1000-2000 kD.
4. The composition of schizophyllan of any one of claims 1-3, wherein the schizophyllan is an oligomeric schizophyllan, and the mass ratio of oligomeric schizophyllan to ergothioneine is (2-4): 1;
preferably, the schizophyllan is a small molecule schizophyllan, and the mass ratio of the small molecule schizophyllan to the ergothioneine is (5-10): 1;
preferably, the schizophyllan is a medium-molecular schizophyllan, and the mass ratio of the medium-molecular schizophyllan to the ergothioneine is (1-2): 1;
preferably, the schizophyllan is macromolecular schizophyllan, and the mass ratio of the macromolecular schizophyllan to the ergothioneine is (0.5-2): 1.
5. The composition of schizophyllan of any one of claims 1-4, wherein the composition of schizophyllan further comprises a solvent;
preferably, the solvent comprises water;
preferably, the composition of the schizophyllan comprises the following components in percentage by mass: 0.01-10% of schizophyllan, 0.05-2% of ergothioneine and the balance of water.
6. A process for the preparation of a composition of schizophyllan according to any one of claims 1 to 5, wherein the process for the preparation of a composition of schizophyllan comprises the steps of: mixing schizophyllan and ergothioneine to obtain the composition of schizophyllan.
7. The method of preparing a composition of schizophyllan according to claim 6, wherein the mixing is carried out in a solvent;
preferably, the temperature of the mixing is 50-90 ℃, and the time of the mixing is 10-50 min.
8. Use of a composition of schizophyllan according to any one of claims 1-5 for the preparation of an antioxidant product.
9. A cosmetic comprising the composition of schizophyllan according to any one of claims 1 to 5.
10. Cosmetic product according to claim 9, characterized in that the composition of schizophyllan is added in an amount of 0.01 to 50%, preferably 0.05 to 20% by weight of the total mass of the cosmetic product.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111615861.7A CN114224778B (en) | 2021-12-27 | 2021-12-27 | Schizophyllum commune polysaccharide composition and preparation method and application thereof |
| JP2022190727A JP2023097373A (en) | 2021-12-27 | 2022-11-29 | Schizophyllan composition as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111615861.7A CN114224778B (en) | 2021-12-27 | 2021-12-27 | Schizophyllum commune polysaccharide composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114224778A true CN114224778A (en) | 2022-03-25 |
| CN114224778B CN114224778B (en) | 2023-02-24 |
Family
ID=80763541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111615861.7A Active CN114224778B (en) | 2021-12-27 | 2021-12-27 | Schizophyllum commune polysaccharide composition and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2023097373A (en) |
| CN (1) | CN114224778B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117530902A (en) * | 2023-12-08 | 2024-02-09 | 广东丸美生物技术股份有限公司 | Acne-removing and inflammation-diminishing composition containing sulfated schizophyllan and application of composition |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117598940B (en) * | 2023-11-16 | 2024-06-21 | 广州中妆美业化妆品有限公司 | Tea tender protein composition with antioxidant, anti-wrinkle and ultraviolet injury repairing effects and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015116173A (en) * | 2013-12-20 | 2015-06-25 | 学校法人武庫川学院 | Ergothioneine-containing composition |
| CN107550753A (en) * | 2017-10-17 | 2018-01-09 | 广州润虹医药科技股份有限公司 | A kind of composition and preparation method thereof with skin repair, anti-senescence function |
| CN112402322A (en) * | 2020-11-30 | 2021-02-26 | 黄丹 | Facial mask liquid capable of promoting expression of aquaporins AQP3 and AQP9 |
-
2021
- 2021-12-27 CN CN202111615861.7A patent/CN114224778B/en active Active
-
2022
- 2022-11-29 JP JP2022190727A patent/JP2023097373A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015116173A (en) * | 2013-12-20 | 2015-06-25 | 学校法人武庫川学院 | Ergothioneine-containing composition |
| CN107550753A (en) * | 2017-10-17 | 2018-01-09 | 广州润虹医药科技股份有限公司 | A kind of composition and preparation method thereof with skin repair, anti-senescence function |
| CN112402322A (en) * | 2020-11-30 | 2021-02-26 | 黄丹 | Facial mask liquid capable of promoting expression of aquaporins AQP3 and AQP9 |
Non-Patent Citations (1)
| Title |
|---|
| 鲁飞飞等: "食用菌的皮肤护理功效以及在化妆品中的应用", 《日用化学品科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117530902A (en) * | 2023-12-08 | 2024-02-09 | 广东丸美生物技术股份有限公司 | Acne-removing and inflammation-diminishing composition containing sulfated schizophyllan and application of composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023097373A (en) | 2023-07-07 |
| CN114224778B (en) | 2023-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114224778B (en) | Schizophyllum commune polysaccharide composition and preparation method and application thereof | |
| US6172250B1 (en) | Preparation process of biologically active silicon compounds in a concentrated form | |
| JP3708540B2 (en) | Stable ascorbic acid composition | |
| US6689349B1 (en) | Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis | |
| CN108143659B (en) | Hydrogen-rich water composition for beautifying and protecting skin, production process thereof and application thereof in cosmetics | |
| JPH0665031A (en) | Application of inactivating substance to radical catcher and/or non-radical active oxygen for preventing or suppressing of | |
| JP6000511B2 (en) | Butyric acid-formic acid mixed esters of acidic polysaccharides and their preparation and use as skin cosmetics | |
| JP2014159488A (en) | Process for purification of heparan sulfate and use thereof in cosmetological and dermatological preparations | |
| CN111888282B (en) | Sunscreen composition containing ultraviolet-absorbable modified biomass, preparation method and application | |
| CN1284327A (en) | Composition for making unstable material of oxygen stabilize | |
| CN108186496B (en) | Whitening and moisturizing skin care product | |
| KR100812129B1 (en) | Cosmetic compositions comprising vitamin c and soluble beta glucan for preventing skin aging | |
| US9649269B2 (en) | Use of glycosaminoglycan lipoate esters in the trichology field | |
| KR20010018665A (en) | A cosmetic composition containing Bambusae caulis in Taenian extracts | |
| KR20070079889A (en) | Anti-aging composition containing cellulixir | |
| KR20130138563A (en) | Antiaging cosmetic composition comprising photoreactive chitosan derivatives and epidermal growth factor immobilized thereon | |
| KR100415430B1 (en) | Cosmetic composition containing stabilized L-ascorbic acid | |
| KR20100045957A (en) | Cosmetic composition with high concentration of stable pure vitamin c in aqueous system | |
| CN107440969B (en) | Sunscreen repairing agent and application thereof | |
| KR20060104008A (en) | Composition for stabilizing vitamin c or its derivative containing a extract from diospyros kaki leaf as active ingredient | |
| KR100803913B1 (en) | Non-sticky and Photo-stable Hydrophilic Transparent Gelling Type Skin-Lotion Composition | |
| US6685965B1 (en) | Process for stabilizing levogyre ascorbic acid (laa), a stable aqueous laa composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment | |
| CN117462430A (en) | Antioxidant composition and application thereof | |
| KR100292143B1 (en) | Cosmetic composition comprising glycollic acid and vitamin C | |
| CN111437217A (en) | Mild-effect-based anti-aging face cream |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |